Immune Restoration Disease in HIV Patients on Antiretroviral Therapy
Author Information
Author(s): Huruy Kahsay, Kassu Afework, Mulu Andargachew, Wondie Yemataw
Primary Institution: Department of Medical Laboratory Technology, College of Medicine and Health Sciences, University of Gondar, Ethiopia
Hypothesis
What is the proportion of immune restoration disease (IRD) and its risk factors in HIV-infected patients during highly active antiretroviral therapy (HAART)?
Conclusion
The study found that 14.6% of HIV-infected patients developed immune restoration disease during the first three months of HAART, primarily associated with low baseline CD4+ T-cell counts and extra pulmonary tuberculosis.
Supporting Evidence
- A total of 1166 HIV-infected patients were included in the study.
- Immune restoration disease was identified in 170 patients, representing 14.6% of the sample.
- Low baseline CD4+ T-cell count was associated with a higher risk of developing IRD.
- Most IRD cases occurred within the first three months of HAART initiation.
- The most common opportunistic infection associated with IRD was tuberculosis.
Takeaway
When people with HIV start treatment, some can get sick again because their immune system is waking up. This study found that about 15 out of 100 people got sick again after starting their medicine.
Methodology
A retrospective study of HIV-infected patients starting HAART was conducted, analyzing clinical and laboratory data from hospital records.
Potential Biases
Potential biases may arise from the retrospective nature of the study and reliance on existing medical records.
Limitations
The study was retrospective and may have limitations in data accuracy and completeness.
Participant Demographics
Mean age of participants was 36 years, with 55.3% being female and 47.7% married.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI, 2.19-4.58 for low baseline CD4+ T-cell count; 95% CI, 3.36-17.65 for extra pulmonary tuberculosis.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website